{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:58:45Z","timestamp":1770271125372,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.waojou.2023.100778","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:46:51Z","timestamp":1684604811000},"page":"100778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug hypersensitivity in drug-resistant tuberculosis"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-6824","authenticated-orcid":false,"given":"Zeynep Yegin","family":"Katran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8111-6149","authenticated-orcid":false,"given":"\u0130smet","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-1558","authenticated-orcid":false,"given":"Aylin","family":"Babal\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Keren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-5662","authenticated-orcid":false,"given":"Fatma Merve","family":"Tepetam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-3237","authenticated-orcid":false,"given":"Selver Seda","family":"Mersin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1047-2004","authenticated-orcid":false,"given":"Cihan","family":"\u00d6r\u00e7en","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-1289","authenticated-orcid":false,"given":"Tu\u011f\u00e7e","family":"Yakut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2023.100778_bib1","series-title":"Global Tuberculosis Report 2021","year":"2021"},{"key":"10.1016\/j.waojou.2023.100778_bib2","series-title":"Guidelines on the Management of Latent Tuberculosis Infection","year":"2015"},{"key":"10.1016\/j.waojou.2023.100778_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.876955","article-title":"Assessment of adverse drug events, their risk factors, and management among patients treated for multidrug-resistant TB: a prospective cohort study from Pakistan","volume":"13","author":"Khan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.waojou.2023.100778_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.883483","article-title":"Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: analysis from a prospective study","volume":"13","author":"Massud","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10150","key":"10.1016\/j.waojou.2023.100778_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.waojou.2023.100778_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1473-3099(17)30449-8","article-title":"Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science","volume":"17","author":"Alffenaar","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.waojou.2023.100778_bib7","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2147\/PPA.S333111","article-title":"Between curing and torturing: burden of adverse reaction in drug-resistant tuberculosis therapy","volume":"15","author":"Ausi","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.waojou.2023.100778_bib8","series-title":"Tuberculosis Diagnosis and Treatment Guide","year":"2019"},{"key":"10.1016\/j.waojou.2023.100778_bib9","unstructured":"Approach to Drug Hypersensitivity Reactions: Turkish National Guideline Updated in 2019."},{"issue":"4","key":"10.1016\/j.waojou.2023.100778_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2023.100778_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13223-022-00737-4","article-title":"Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: successful desensitization","volume":"18","author":"Katran","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.waojou.2023.100778_bib12","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2147\/IDR.S351076","article-title":"A\u00a0score to predict the risk of major adverse drug reactions among multi-drug resistant tuberculosis patients in southern Ethiopia, 2014-2019","volume":"15","author":"Bogale","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.waojou.2023.100778_bib13","article-title":"Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: a countrywide 5-year retrospective study","volume":"23","author":"Baluku","year":"2021","journal-title":"J\u00a0Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.waojou.2023.100778_bib14","article-title":"Frequency and factors associated with adverse events among multi-drug resistant tuberculosis patients in Pakistan: a retrospective study","volume":"8","author":"Atif","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.waojou.2023.100778_bib15","first-page":"6","article-title":"The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia","volume":"5","author":"Sagwa","year":"2012","journal-title":"South Med Rev"},{"issue":"9","key":"10.1016\/j.waojou.2023.100778_bib16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.waojou.2023.100778_bib17","first-page":"143","article-title":"Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs","volume":"62","author":"Tan","year":"2007","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.waojou.2023.100778_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijid.2021.03.093","article-title":"Isoniazid-monoresistant tuberculosis in France: risk factors, treatment outcomes and adverse events","volume":"107","author":"Bachir","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.waojou.2023.100778_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259221","article-title":"Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda","volume":"16","author":"Micheni","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.waojou.2023.100778_bib20","first-page":"90","article-title":"Factors contributing to drug-resistant tuberculosis treatment outcome in five countries in the Eastern Europe and Central Asia region","author":"Auer","year":"2020","journal-title":"Monaldi Arch Chest Dis"},{"issue":"4","key":"10.1016\/j.waojou.2023.100778_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.waojou.2023.100778_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pulmoe.2020.03.005","article-title":"First case report in Latin America: oral treatment of multidrug-resistant tuberculosis with delamanid and bedaquiline in combination with linezolid, moxifloxacin and clofazimine following a DRESS syndrome in a peruvian patient","volume":"27","author":"Pecho-Silva","year":"2021","journal-title":"Pulmonology"},{"issue":"2","key":"10.1016\/j.waojou.2023.100778_bib23","first-page":"187","article-title":"Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis","volume":"1","author":"Akula","year":"1997","journal-title":"Int J Tubercul Lung Dis"},{"issue":"1","key":"10.1016\/j.waojou.2023.100778_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/ijd.ijd_169_21","article-title":"Lichenoid drug eruption progressing into erythroderma in A case of cervical scrofuloderma due to multi drug-resistant tuberculosis","volume":"67","author":"Kura","year":"2022","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100778_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/idoj.IDOJ_133_19","article-title":"Spectrum of cutaneous adverse drug reactions to anti-tubercular drugs and safe therapy after Re-challenge - a retrospective study","volume":"11","author":"Sharma","year":"2020","journal-title":"Indian Dermatol Online J"},{"issue":"7","key":"10.1016\/j.waojou.2023.100778_bib26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/thx.53.7.536","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint tuberculosis committee of the British thoracic society","volume":"53","year":"1998","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.waojou.2023.100778_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/1871528113666140717113358","article-title":"Cutaneous adverse drug reactions caused by antituberculosis drugs","volume":"13","author":"Rezakovic","year":"2014","journal-title":"Inflamm Allergy Drug Targets"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:46:24Z","timestamp":1761849984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455123000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1939455123000388"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100778","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug hypersensitivity in drug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100778"}}